National Trends of Antiparkinsonism Treatment in Taiwan: 2004–2011
Background. Several guidelines for Parkinson’s disease (PD) management were recently updated. We examined temporal trends for antiparkinsonism drugs in Taiwan. Methods. Antiparkinsonism prescriptions, including levodopa, ergot/nonergot dopamine agonists (DAs), amantadine, selegiline, entacapone, and...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2016/1859321 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561193441558528 |
|---|---|
| author | Weng-Ming Liu Ruey-Meei Wu Chia-Hsuin Chang Jou-Wei Lin Ying-Chun Liu Chin-Hsien Lin |
| author_facet | Weng-Ming Liu Ruey-Meei Wu Chia-Hsuin Chang Jou-Wei Lin Ying-Chun Liu Chin-Hsien Lin |
| author_sort | Weng-Ming Liu |
| collection | DOAJ |
| description | Background. Several guidelines for Parkinson’s disease (PD) management were recently updated. We examined temporal trends for antiparkinsonism drugs in Taiwan. Methods. Antiparkinsonism prescriptions, including levodopa, ergot/nonergot dopamine agonists (DAs), amantadine, selegiline, entacapone, and anticholinergics, were identified in the Taiwan National Health Insurance Database from 2004 to 2011. Time trend analyses were estimated assuming Poisson distribution. Results. A total of 19,302 PD patients in 2004 and 41,606 PD patients in 2011 were analyzed. Antiparkinsonism prescriptions increased significantly from 187,137 in 2004 to 414,587 in 2011. Levodopa monotherapy or combination therapy was the mainstay. Levodopa monotherapy comprised 37.4% of prescriptions in 2004 and 44.2% in 2011, with an annual increase rate of 18.14%. There was a substantially increasing trend of DA prescriptions, which were higher in younger-aged patients (<60 years) than in older-aged group (p=0.0006). Among combination therapy, DA combined with levodopa or other antiparkinsonism medications became the main combinations for younger-aged patients after 2009. After 2005, the proportion of ergot DA usage markedly decreased and PD patients using nonergot DA increased. Conclusions. Levodopa was the major treatment from 2004 to 2011. There was a steeply increased trend of DA use, especially in younger-aged patients. Nonergot agents comprised the major DA group after 2005. |
| format | Article |
| id | doaj-art-0318281ad35e454498d13d7759497684 |
| institution | Kabale University |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-0318281ad35e454498d13d77594976842025-02-03T01:25:38ZengWileyParkinson's Disease2090-80832042-00802016-01-01201610.1155/2016/18593211859321National Trends of Antiparkinsonism Treatment in Taiwan: 2004–2011Weng-Ming Liu0Ruey-Meei Wu1Chia-Hsuin Chang2Jou-Wei Lin3Ying-Chun Liu4Chin-Hsien Lin5Department of Neurology, Buddhist Tzu Chi General Hospital, Hualien, TaiwanDepartment of Neurology, National Taiwan University Hospital, No. 7, Chunag-Shan South Road, Taipei 100, TaiwanDepartment of Medicine, College of Medicine, National Taiwan University, Taipei, TaiwanDepartment of Medicine, College of Medicine, National Taiwan University, Taipei, TaiwanInstitute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, TaiwanDepartment of Neurology, National Taiwan University Hospital, No. 7, Chunag-Shan South Road, Taipei 100, TaiwanBackground. Several guidelines for Parkinson’s disease (PD) management were recently updated. We examined temporal trends for antiparkinsonism drugs in Taiwan. Methods. Antiparkinsonism prescriptions, including levodopa, ergot/nonergot dopamine agonists (DAs), amantadine, selegiline, entacapone, and anticholinergics, were identified in the Taiwan National Health Insurance Database from 2004 to 2011. Time trend analyses were estimated assuming Poisson distribution. Results. A total of 19,302 PD patients in 2004 and 41,606 PD patients in 2011 were analyzed. Antiparkinsonism prescriptions increased significantly from 187,137 in 2004 to 414,587 in 2011. Levodopa monotherapy or combination therapy was the mainstay. Levodopa monotherapy comprised 37.4% of prescriptions in 2004 and 44.2% in 2011, with an annual increase rate of 18.14%. There was a substantially increasing trend of DA prescriptions, which were higher in younger-aged patients (<60 years) than in older-aged group (p=0.0006). Among combination therapy, DA combined with levodopa or other antiparkinsonism medications became the main combinations for younger-aged patients after 2009. After 2005, the proportion of ergot DA usage markedly decreased and PD patients using nonergot DA increased. Conclusions. Levodopa was the major treatment from 2004 to 2011. There was a steeply increased trend of DA use, especially in younger-aged patients. Nonergot agents comprised the major DA group after 2005.http://dx.doi.org/10.1155/2016/1859321 |
| spellingShingle | Weng-Ming Liu Ruey-Meei Wu Chia-Hsuin Chang Jou-Wei Lin Ying-Chun Liu Chin-Hsien Lin National Trends of Antiparkinsonism Treatment in Taiwan: 2004–2011 Parkinson's Disease |
| title | National Trends of Antiparkinsonism Treatment in Taiwan: 2004–2011 |
| title_full | National Trends of Antiparkinsonism Treatment in Taiwan: 2004–2011 |
| title_fullStr | National Trends of Antiparkinsonism Treatment in Taiwan: 2004–2011 |
| title_full_unstemmed | National Trends of Antiparkinsonism Treatment in Taiwan: 2004–2011 |
| title_short | National Trends of Antiparkinsonism Treatment in Taiwan: 2004–2011 |
| title_sort | national trends of antiparkinsonism treatment in taiwan 2004 2011 |
| url | http://dx.doi.org/10.1155/2016/1859321 |
| work_keys_str_mv | AT wengmingliu nationaltrendsofantiparkinsonismtreatmentintaiwan20042011 AT rueymeeiwu nationaltrendsofantiparkinsonismtreatmentintaiwan20042011 AT chiahsuinchang nationaltrendsofantiparkinsonismtreatmentintaiwan20042011 AT jouweilin nationaltrendsofantiparkinsonismtreatmentintaiwan20042011 AT yingchunliu nationaltrendsofantiparkinsonismtreatmentintaiwan20042011 AT chinhsienlin nationaltrendsofantiparkinsonismtreatmentintaiwan20042011 |